Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo

Journal of Medicinal Chemistry

Volumn 51, Issue 8, 2008, Pages 2457-2467

  Smits, Rogier A ^a   Lim, Herman D ^a   Hanzer, Agnes ^a   Zuiderveld, Obbe P ^a   Guaita, Elena ^b   Adami, Maristella ^b   Coruzzi, Gabriella ^b   Leurs, Rob ^a   De Esch, Iwan J P ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZYL 3 (4 PIPERAZIN 1 YL)QUINOXALINE; 2, 3 DICHLOROQUINOXALINE; 6,7 DICHLORO 3 (4 PIPERAZIN 1 YL)QUINOXALIN 2 (1H)ONE; HISTAMINE H4 RECEPTOR; QUINOXALINE DERIVATIVE; VUF 10148; VUF 10214;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PAW EDEMA; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; RECEPTORS, HISTAMINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43049083344     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7014217     Document Type: Article

References (34)

1. Hiff, S. J. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 1990, 42, 45-83.
2. 2-receptors. Nature 1972, 236, 385-390.
3. 3 receptor antagonists reach out for the clinic. Drug Discovery Today. 2005, 23/24, 1613-1627.
4. 4) expressed in hone marrow. Mol. Pharmacol. 2001, 59, 420-426.
5. Morse, K. L.; Behan, J.; Laz, T. M.; West, R. E., Jr.; Greenfender, S. A.; Anthes, J. C.; Umland, S.; Wan, Y.; Hipkin, R. W.; Gonsiorek, W.; Shin, N.; Gustafson, E. L.; Qiao, X.; Wang, S.; Hedrick, J. A.; Green, J.; Buyne, M.; Monsma, F. J., Jr. Cloning and characterization of a novel human histamine receptor. J. Pharmacol. Exp. Ther. 2001, 296, 1058-1066.
6. Nguyen, T.; Shapiro, D. A.; George, S. R.; Setola, V.; Lee, D. K.; Cheng, R.; Rauser, L.; Lee, S. P.; Lynch, K. R.; Roth, B. L.; O'Dowd, B. F. Discovery of a novel member of the histamine receptor family. Mol. Pharmacol. 2001, 59, 427-433.
7. Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000, 275, 36781-36786.
8. Zhu, Y.; Michalovich, D.; Wu, H-L.; Tan, K. B.; Dytko, G. M.; Mannan, I. J.; Boyee, R.; Alston, J.; Tierney, L. A.; Li, X.; Herrity, N. C.; Vawter, L.; Sarau, H. M.; Ames, R. S.; Davenpor., C. M.; Hieble, J. P.; Wilson, S.; Bergsma, D. J.; Fitzgerald, L. R. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 2001, 59, 434-444.
9. 4 receptor as a new therapeutic target for inflammation. Trends Pharmacol. Sci. 2005, 26, 462-9.
10. 2 receptors control histamine-induced interleukin-16 release from human CD8' T cells. J. Pharmacol. Exp. Ther. 2002, 303, 300-7.
11. 4 receptor antagonists on experimental colitis in the rat. Eur. J. Pharmacol. 2005, 522, 130-138.
12. 4 receptor antagonist with anti-inflammatory properties. J. Pharmacol. Exp. Ther. 2004, 309, 404-413.
13. 4 receptor expression iu human synovial cells obtained from patients suffering from rheumatoid arthritis. Biol. Pharm. Bull. 2005, 10, 2016-2018.
14. 1 receptors in scratching induced bv histamine receptor agonists in BaIbC mice. Br. J. Pharmacol. 2004, 142, 374-380.
15. Cianchi, F.; Cortesini, C.; Schiavone, N.; Perna, F.; Magnelli, L.; Fanti, E.; Bani, D.; Messerini, L.; Fabbroni, V.; Perigli, G.; Capaccioli, S.; Masini, E. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin. Cancer Res. 2005, (19 Pt 1), 6807-6815.
16. 4 receptor binding site: Part I. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J. Med. Chem. 2006, 49, 4512-4516.
17. Jahlonowski, J. A.; Grice, C. A.; Chai, W.; Dvorak, C. A.; Venable, J. D.; Kwok, A. K.; Ly, K. S.; Wei, J.; Baker, S. M.; Desai, P. J.; Jiang, W.; Wilson, S. J.; Thurmond, R. L.; Karlsson, L.; Edwards, J. P.; Lovenherg, T. W.; Carruthers, N. I. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J. Med. Chem. 2003, 46, 3957-3960.
18. 4 antagonists. J. Med. Chem. 2005, 48, 8289-8298.
19. Greenlee, W.; Gangly, A.; Wasley, J. W. F. Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) prperazines, dopamine receptor subtype specific ligands. U.S. Patent US 6.040.448. 2000.
20. Lawrence, D. S.; Copper, J. E.; Smith, C. D. Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. J. Med. Chem. 2001, 44, 594-601.
21. Duffy, K. J.; Haltiwanger, R. C.; Huang, Y.; Kanialian-Beck, A.; Luengo, J. I. A novel synthesis of 2-(2-quinoxalino)-3,5-diarylfurans. Tetrahedron Lett. 1998, 39, 8017-8020.
22. Mustafa, M. E.; Takaoka, N.; Ishikawa, N. Trifluoropynivic acid hydrate in heterocyclic synthesis. Synthesis of trifluoromcthylaled five, six, and seven memhered heterocycles with two or more heteroatoms. Bull. Soc. Chim. Fr. 1986, 944-954.
23. 3 antagonists. Chem. Pharm. Bull. 1993, 41, 1832-1841.
24. Sarges, R.; Howard, H. R.; Browne, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, K. 2-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem. 1990, 33, 2240-2254.
25. Cannizzo, S.; Guerrera, F.; Siracusa, M. A. Synthesis of substituted [1]benzothieno[2,3-b]pyrazines. J. Heterocycl. Chem. 1990, 27, 2175-79.
26. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
27. Quinoxaline compounds. U. S. Patent US2005/0070527 A1, 2005.
28. 4 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5251-5256.
29. Sato, H.; Tanaka, K.; Shimazaki, M.; Urbahns, K.; Sakai, K.; Gantner, F.; Bacon, K. 2-Aminopyrimidine derivatives. Patent WO/2005/054239, 2005.
30. Dyke, H.; Price, S.; Cramp, S. Pyrimidine compounds for the treatment of inflammatory disorders. European Patent EP1767537A1, 2007.
31. 4 antagonism: a therapy for chronic allergy. Br. J. Pharmacol. 2004, 142, 5-7.
32. Ganellin, C. R.; Hosseini, S. K.; Khalaf, Y. S.; Tertink, W.; Arrang, J. M.; Garbarg, M.; Ligneau, X.; Schwartz, J. C. Design of potent non-thiourea H3 receptor antagonists. J. Med. Chem. 1995, 38, 3342 3350.
33. 4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced inflammation. Eur. J. Pharmacol. 2007, 563, 240-244.
34. Bakker, R. A.; Weiner, D. M.; ter Laak, T.; Beuming, T.; Zuiderveld, O. P.; Edelbroek, M.; Hacksell, U.; Timmerman, H.; Brann, M. R.; Leurs, R. 8R-Iisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol. Pharmacol. 2004, 65, 538-549.